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TO THE EDITOR
EGFR is the prototypical member of the
avian erythroblastosis oncogene B
(ErbB) network comprising four trans-
membrane receptor tyrosine kinases
(EGFR/ErbB1, ErbB2, ErbB3, and ErbB4).
These receptors bind EGF and heregulin
family ligands in a dynamic, feedback-
regulated manner, activating multiple
signal transduction pathways and ulti-
mately affecting many cellular functions
(Wilson et al., 2009; Avraham and
Yarden, 2011). ErbB receptors and
their ligands are overexpressed in a
wide spectrum of hyperplastic
epithelial disorders including psoriasis
and cancers. Numerous monoclonal
antibodies and receptor tyrosine kinase
inhibitors have been designed to block
their activation (Yarden and Pines,
2012) and are highly effective for
treating colorectal and non–small cell-
lung cancers. However, skin toxicity is
frequently observed in patients under-
going therapy with EGFR inhibitors
(EGFRIs; Lacouture, 2006), including
papular and pustular eruptions of the
face and trunk, nail changes, dry skin,
itch, and hair loss (Lacouture and Lai,
2006). These side effects are the major
dose-limiting toxicity of EGFRI therapy
(Boone et al., 2007) and emphasize the
importance of understanding the
mechanisms involved.
Keratinocyte (KC)-Tie2 mice develop
marked skin inflammation and epider-
mal hyperplasia, which is suppressible
by cyclosporin A (Wolfram et al., 2009),
tumor necrosis factor-a (TNFa; Ward
et al., 2011b), or vascular endothelial
growth factor inhibition (Diaconu et al.,
2013). In the course of experiments
designed to identify the cause of this
inflammatory hyperplasia, we observed
a time-dependent increase in the
expression of transcripts encoding the
EGFR ligands amphiregulin, heparin-
binding EGF-like growth factor,
epiregulin, and epigen in full-thickness
dorsal skin using quantitative real-time
reverse-transcriptase–PCR (qRT-PCR).
These increases were much greater in
KC-Tie2 double transgenic (DT) mice
relative to wild-type (WT) or single
transgenic (ST) littermate controls
(Figure 1a–d). To test the hypothesis that
these EGFR ligands might be driving the
observed inflammation, and that pre-
vention of EGFR signaling would pre-
vent phenotype development, we
treated a group of KC-Tie2 DT mice
and control littermates with intraperito-
neal administration of erlotinib
(10 mg kg1 erlotinib HCl, LC Labora-
tories, Woburn, MA) or vehicle for 28
days, beginning at postnatal day 10,
emulsifying the erlotinib in Captisol
(Cydex Pharmaceuticals, Lenexa, KS)
as described (Zerbe et al., 2008), and
then analyzed the skin phenotype in a
blinded manner as described previously
(Wolfram et al., 2009). All mouse
experiments were approved by the
Institutional Animal Care and Use
Committee of Case Western Reserve
University School of Medicine. Despite
the fact that we could demonstrate
erlotinib inhibition of UV light–
induced EGFR and extracellular signal–
regulated kinase activation (data not
shown), KC-Tie2 mice treated with erlo-
tinib showed a marked increase in skin
inflammation relative to saline-treated
KC-Tie2 mice (Figure 1), whereas erlo-
tinib treatment of WT and ST littermates
displayed no changes compared with
saline treatment (data not shown). The
increase in epidermal thickness as well
as CD4þ (Figure 1) and F4/80þ
immune cell infiltrates (Supplementary
Figure 1a online) was accompanied by a
6.7-fold increase in Il1b messenger RNA
in erlotinib-treated KC-Tie2 skin by qRT-
PCR (P¼0.035, Supplementary Figure 2
online), with no effect in erlotinib-trea-
ted littermate controls (data not shown).
These findings are consistent with
prior reported adverse effects of EGFRI
therapy (Lacouture, 2006) and a
previous study of EGFRI-induced
inflammation in mouse skin
(Surguladze et al., 2009). On the basis
of these studies as well our observation
of increased Il1b, we hypothesized that
erlotinib-mediated inflammatory
hyperplasia in KC-Tie2 mice is at least
in part mediated by IL-1.
To test this hypothesis, mice were
treated daily with vehicle, erlotinib
(10 mg kg1), the IL-1 receptor antago-
nist anakinra (100 mg kg1), or erlotinib
and anakinra together, using the same
approach described above. These doses
correspond to therapeutic human
in vivo patient levels for both erlotinib
and anakinra. Notably, the erlotinib-
mediated increases in epidermal thick-
ness and CD4þ T cells (Figure 1) and
F4/80þ macrophages (Supplemen-
tary Figure 1 online) were abrogated
by anakinra. Although CD8þ T cells
and CD11cþ dendritic cells were sig-
nificantly increased in KC-Tie2 mouse
skin compared with littermate controls,
there was no significant further increase
or decrease in response to erlotinib or
anakinra, respectively (Supplementary
Figure 1 online). Although anakinra
was able to reverse the pro-inlfamma-
tory effects of ertlotinib in KC-Tie2 mice,
the lack of efficacy of erlotinib and
anakinra as individual agents in resol-
ving the psoriasiform skin inflammation
that arises spontaneously in this model
is consistent with the lack of reported
efficacy of each of these inhibitors for
treating psoriasis.Accepted article preview online 13 October 2014; published online 6 November 2014
Abbreviations: CNU, cutaneous neurovascular unit; DT, double transgenic; EGFRI, EGFR inhibitor; ErbB,
avian erythroblastosis oncogene B; KC, keratinocyte; qRT-PCR, quantitative real-time reverse-transcriptase–
PCR; ST, single transgenic; WT, wild type
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In parallel to the murine work, we
conducted translational experiments
using human skin organ cultures
(Varani et al., 1993), examining the
pro-inflammatory effects of erlotinib
and the role of IL-1. The participation
of human subjects in this study was
approved by the University of Michigan
Institutional Review Board and subjects
provided written informed consent prior
to inclusion in the study. Treatment of
human skin organ cultures with erlotinib
(2 mm punch biopsies from hip skin of
volunteers) led to significant increases in
epidermal thickness (Figure 2), which
was dose dependent and was prevented
by 20mg ml 1 anakinra, and had no
significant effect on its own (Figure 2).
EGFRIs potentiate the induction of che-
mokines such as CCL2, CCL5, and
CXCL10 by TNF and IFN-g in
keratinocytes (Mascia et al., 2003) and
CCL2 induction has been observed
immunohistochemically in the skin of
cancer patients treated with the EGFRI
gefitinib (Yamaki et al., 2010).
Accordingly, we found that erlotinib
significantly increased elaboration of
CCL2 and MMP-1 into the organ culture
medium, and these increases were
blocked by anakinra (Figure 2g and h).
One final question concerns why
erlotinib-mediated inflammatory events
occur in organ cultures of normal
human skin, whereas they do not
occur in phenotypically normal WT or
ST mouse skin lacking Tie2 overexpres-
sion. Although KCs constitutively ex-
press angiopoietin (Larcher et al.,
2003; Ward et al., 2011a), they
express little to no endogenous Tie2
(Voskas et al., 2005; Wolfram et al.,
2009). The expression of both genes in
the epidermal compartment has been
shown to activate the cutaneous
neurovascular unit (CNU; Ward et al.,
2011a), at least in part by activating an
autocrine signal transduction cascade in
KCs that is not normally present
(Wolfram et al., 2009). Many nerves
and vessels are present in human skin,
richly investing the hair follicles and
eccrine glands. We would speculate
that the CNU becomes activated in
human skin organ cultures because of
biopsy-induced trauma to the CNU,
whereas it becomes activated in
response to Ang1-Tie2 signaling in KC-
Tie2 mice (Ward et al., 2011a). It is
possible that an altered skin homeostasis
involving the CNU may also be present
in the subset of erlotinib-treated patients
in whom skin rash develops.
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Figure 1. EGFR ligand expression increases in keratinocyte (KC)-Tie2 mouse skin during development of the inflammatory phenotype, and erlotinib treatment
increases epidermal thickness and immunocyte infiltration into the skin, which is abrogated following anakinra treatment. EGFR ligand messenger RNA
expression (amphiregulin (a), epiregulin (b), epigen (c), and Hbegf (d)) increases during development of the in KC-Tie2 skin phenotype. mRNA expression values
are normalized to 18S rRNA and are expressed relative to week 1. Erlotinib-treated KC-Tie2 mice have increases in epidermal thickness (f and i) and CD4þ T-cell
skin infiltration (f, j) compared with vehicle (e) and anakinra alone (g), and this increase is abrogated with concomitant anakinra treatment (h–j). Photomicrographs
depict CD4þ T-cell immunohistochemistry with diaminobenzidine (DAB) as the chromogen. Slides are counterstained with hematoxylin. Bar ¼ 100mm. Bars,
meanþ SEM (n¼ 3–4 for a–d and n¼7–22 for i and j). Statistical significance indicated by *Po0.05 and **Po0.005, using unpaired multiple t-tests with Holm–
Sidak correction for multiple comparisons.
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Our results suggest that the cutaneous
pro-inflammatory effects of erlotinib are
IL-1 mediated in human and mouse
skin. These findings support the notion
that IL-1 inhibition may serve as a useful
tool for either preventing or attenuating
the dose-limiting side effects, specifi-
cally the skin toxicity, observed in
patients undergoing therapy with
EGFRIs (Lacouture, 2006). Our results
also suggest that a simple autocrine
EGFR-ligand–driven loop is unlikely to
drive keratinocyte proliferation in either
mouse or human skin, as envisioned
in some earlier models of epidermal
hyperplasia (Elder et al., 1989). Rather,
EGFR signaling appears to be anti-
inflammatory, with the increases in
EGFR ligand expression that are
observed in psoriasis (Johnston et al.,
2011) and in KC-Tie2 mice (Wolfram
et al., 2009) serving as a negative
feedback mechanism. If so, this may
explain why no successful controlled
trials of EGFRIs as a therapeutic
modality in psoriasis have appeared,
despite their availability. Further
exploration of other models in which
skin homeostasis is altered is warranted
to test this hypothesis in other contexts.
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TO THE EDITOR
Fogo selvagem (FS) is an endemic form
of pemphigus foliaceus, which is pre-
valent in certain regions of Brazil (Diaz
et al., 1989). Genetic and environ-
mental factors such as insect bites may
contribute to the development of FS
(Diaz et al., 1989; Moraes et al., 1997;
Aoki et al., 2004). Blister formation in FS
is mediated by predominantly IgG4 anti-
desmoglein 1 (Dsg1) antibodies (Rock
et al., 1989), which are predictors of FS
(Qaqish et al., 2009). Our recent studies
demonstrate that FS IgG4 antibodies
cross-react with LJM11, a salivary pro-
tein from sand fly Lutzomyia longipalpis
(Qian et al., 2012), suggesting that sand
fly bites may deliver the antigen(s) that
have a role in driving the development
of these IgG4 autoantibodies in FS.
The concomitant development of IgE
and IgG4 has been well documented in
allergy (Lichtenstein et al., 1968; Muller,
2005). In addition, insect bites are
known to induce IgE responses. IgE
response in pemphigus vulgaris and FS
has been described by Nagel et al.
(2009) and us (Qian et al., 2011,
2012). We have demonstrated that FS
patients have significantly higher IgG4
and IgE against sand fly salivary gland
antigens (SGLL) and monoclonal IgG4
autoantibodies derived from FS patients
cross-react with LJM11, a major
immunogenic component from SGLL
(Qian et al., 2012). In this study, we
seek to determine whether IgE
antibodies to either autoantigen (Dsg1)
and/or environmental antigen (LJM11)
are present among individuals living in
FS endemic regions. All serum samples
from controls and patients in this
investigation were obtained from
individuals studied during the last 25
years and kept in a bank of sera at
the University of North Carolina
Dermatology Research Laboratories.
These studies are approved by the
institutional review boards from the
University of North Carolina, Chapel
Hill, and the University of Sao Paulo,
Sao Paulo, Brazil. Randomly selected
serum samples (n¼30) from FS patients,
as well as serum samples of healthy
control (HC) individuals from FS
endemic region (n¼32), Limao VerdeAccepted article preview online 6 October 2014; published online 6 November 2014
Abbreviations: Dsg1, desmoglein 1; FS, fogo selvagem; HC, healthy control; LV, Limao Verde in Brazil;
RLUs, relative light units; SGLL, salivary gland antigens from sand fly (Lutzomyia longipalpis)
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